RGNX Revenue Flow
Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.
- 2026-06-30: Revenue $108.02M; Revenue including tax $108.02M; Cost of revenue (m); Research and development $56.09M.
- 2026-03-31: Revenue $6.39M; Revenue including tax $6.39M; Cost of revenue (m); Research and development $57.34M.
- 2025-12-31: Revenue $30.34M*; Revenue including tax $30.34M*; Cost of revenue (m); Research and development $59.61M*.
- 2025-09-30: Revenue $29.73M; Revenue including tax $29.73M; Cost of revenue (m); Research and development $56.10M.
Consolidation item
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Product or service
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Related Party Transactions By Related Party
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.
Historical revenue and expense breakdown
Revenue and expense 3 month
| Period end | Revenue | Revenue including tax | Cost of revenue | Research and development | Income tax | Net income |
|---|---|---|---|---|---|---|
| 2026-06-30 | $108.02M | $108.02M | (m) | $56.09M | (m) | $22.71M |
| 2026-03-31 | $6.39M | $6.39M | (m) | $57.34M | (m) | -$90.05M |
| 2025-12-31 | $30.34M* | $30.34M* | (m) | $59.61M* | (m) | -$67.15M* |
| 2025-09-30 | $29.73M | $29.73M | (m) | $56.10M | (m) | -$61.94M |
| 2025-06-30 | $21.36M | $21.36M | (m) | $59.50M | (m) | -$70.87M |
| 2025-03-31 | $89.01M | $89.01M | (m) | $53.09M | (m) | $6.08M |
| 2024-12-31 | (m) | (m) | $6.32M* | (m) | (m) | (m) |
| 2024-09-30 | $24.20M | $24.20M | $12.39M | $54.43M | (m) | -$59.60M |
| 2024-06-30 | $22.30M | $22.30M | $10.58M | $48.87M | (m) | -$52.99M |
| 2024-03-31 | $15.62M | $15.62M | $4.28M | $54.84M | (m) | -$63.33M |
| 2023-09-30 | $28.91M | (m) | $12.39M | $58.18M | (m) | -$61.87M |
| 2023-06-30 | $19.98M | (m) | $9.47M | $59.89M | (m) | -$72.06M |
| 2023-03-31 | $19.14M | (m) | $4.11M | $58.52M | (m) | -$66.68M |
| 2022-09-30 | $26.51M | (m) | $13.09M | $63.31M | (m) | -$75.48M |
| 2022-06-30 | $32.65M | (m) | $12.95M | $61.01M | (m) | -$68.18M |
| 2022-03-31 | $22.22M | (m) | $15.72M | $55.63M | -$41.00K | -$76.72M |
| 2021-09-30 | $30.77M | $30.25M | $14.11M | $47.85M | (m) | -$58.41M |
| 2021-06-30 | $22.04M | $18.43M | $9.82M | $45.88M | (m) | -$57.64M |
| 2021-03-31 | $18.88M | $18.26M | $4.85M | $39.72M | $4.00K | -$50.14M |
| 2020-12-31 | $21.45M | (m) | (m) | $47.18M | (m) | -$46.24M |
| 2020-09-30 | $98.91M | $98.80M | $17.36M | $43.97M | -$3.00K | $8.79M |
| 2020-06-30 | $16.57M | $15.45M | $4.68M | $38.11M | -$500.00K | -$33.76M |
| 2020-03-31 | $17.64M | $9.98M | $3.41M | $37.03M | (m) | -$40.04M |
| 2019-12-31 | $11.77M | (m) | (m) | $33.81M | (m) | -$26.46M |
| 2019-09-30 | $14.70M | $9.18M | $2.49M | $35.69M | -$165.00K | -$34.58M |
| 2019-06-30 | $7.88M | $4.42M | $1.93M | $29.48M | -$129.00K | -$1.46M |
| 2019-03-31 | $884.00K | (m) | $29.00K | $25.20M | $70.00K | -$32.23M |
| 2018-12-31 | $40.78M | (m) | (m) | $24.33M | (m) | $4.31M |
| 2018-09-30 | $5.31M | $4.00M | $517.00K | $18.51M | -$1.29M | -$19.20M |
| 2018-06-30 | $40.03M | (m) | $3.87M | $21.49M | $3.85M | $10.59M |
| 2018-03-31 | $132.39M | (m) | $2.41M | $19.55M | (m) | $104.24M |
| 2017-12-31 | $2.04M | (m) | (m) | $14.17M | (m) | -$16.00M |
| 2017-09-30 | $1.34M | (m) | (m) | $12.52M | (m) | -$20.71M |
| 2017-06-30 | $6.56M | (m) | (m) | $13.92M | (m) | -$14.47M |
| 2017-03-31 | $455.00K | (m) | (m) | $16.62M | (m) | -$21.99M |
| 2016-12-31 | $1.70M | (m) | (m) | $16.06M | (m) | -$19.61M |
| 2016-09-30 | $125.00K | (m) | (m) | $12.56M | (m) | -$18.15M |
| 2016-06-30 | $2.38M | (m) | (m) | $10.68M | (m) | -$14.44M |
| 2016-03-31 | $393.00K | (m) | (m) | $6.18M | (m) | -$10.77M |
| 2015-12-31 | $4.44M | (m) | (m) | $4.81M | (m) | -$5.18M |
| 2015-09-30 | $1.14M | (m) | (m) | $5.66M | (m) | -$7.33M |
| 2015-06-30 | $1.36M | (m) | (m) | $4.01M | (m) | -$6.29M |
| 2015-03-31 | $644.00K | (m) | (m) | $2.79M | (m) | -$4.01M |
| 2014-12-31 | $1.15M | (m) | (m) | (m) | (m) | -$2.33M |
| 2014-09-30 | $483.00K | (m) | (m) | $1.08M | (m) | -$1.79M |
| 2014-06-30 | $1.55M | (m) | (m) | (m) | (m) | -$672.00K |
| 2014-03-31 | $2.94M | (m) | (m) | (m) | (m) | $795.00K |
Revenue and expense 6 month
| Period end | Revenue | Revenue including tax | Cost of revenue | Research and development | Income tax | Net income |
|---|---|---|---|---|---|---|
| 2026-06-30 | $114.41M | $114.41M | (m) | $113.42M | (m) | -$67.34M |
| 2025-06-30 | $110.37M | $110.37M | (m) | $112.59M | (m) | -$64.79M |
| 2024-06-30 | $37.92M | $37.92M | $14.86M | $103.71M | (m) | -$116.32M |
| 2023-06-30 | $39.12M | (m) | $13.59M | $118.40M | (m) | -$138.74M |
| 2022-06-30 | $54.87M | (m) | $28.67M | $116.64M | -$41.00K | -$144.90M |
| 2021-06-30 | $40.92M | $36.69M | $14.67M | $85.60M | $4.00K | -$107.78M |
| 2020-06-30 | $34.21M | $25.42M | $8.09M | $75.15M | -$500.00K | -$73.80M |
| 2019-06-30 | $8.77M | $4.42M | $1.96M | $54.69M | -$199.00K | -$33.69M |
| 2018-06-30 | $172.42M | (m) | $6.28M | $41.04M | $3.85M | $114.83M |
| 2017-06-30 | $7.02M | (m) | (m) | $30.54M | (m) | -$36.47M |
| 2016-06-30 | $2.77M | (m) | (m) | $16.86M | (m) | -$25.20M |
| 2015-06-30 | $2.01M | (m) | (m) | $6.80M | (m) | -$10.30M |
Revenue and expense 9 month
| Period end | Revenue | Revenue including tax | Cost of revenue | Research and development | Income tax | Net income |
|---|---|---|---|---|---|---|
| 2025-09-30 | $140.10M | $140.10M | (m) | $168.69M | (m) | -$126.73M |
| 2024-09-30 | $62.11M | $62.11M | $27.25M | $158.14M | (m) | -$175.92M |
| 2023-09-30 | $68.03M | (m) | $25.98M | $176.59M | (m) | -$200.60M |
| 2022-09-30 | $81.38M | (m) | $41.76M | $179.95M | -$41.00K | -$220.39M |
| 2021-09-30 | $71.69M | $66.95M | $28.77M | $133.46M | $4.00K | -$166.18M |
| 2020-09-30 | $133.12M | $124.22M | $25.46M | $119.11M | -$503.00K | -$65.01M |
| 2019-09-30 | $23.46M | $13.61M | $4.45M | $90.38M | -$364.00K | -$68.27M |
| 2018-09-30 | $177.73M | $176.07M | $6.80M | $59.54M | $2.56M | $95.63M |
| 2017-09-30 | $8.35M | (m) | (m) | $43.05M | (m) | -$57.17M |
| 2016-09-30 | $2.89M | (m) | (m) | $29.42M | (m) | -$43.36M |
| 2015-09-30 | $3.14M | (m) | (m) | $12.47M | (m) | -$17.64M |
| 2014-09-30 | $4.97M | (m) | (m) | $2.87M | (m) | -$1.67M |
Revenue and expense 12 month
| Period end | Revenue | Revenue including tax | Cost of revenue | Research and development | Income tax | Net income |
|---|---|---|---|---|---|---|
| 2025-12-31 | $170.44M | $170.44M | (m) | $228.30M | $0.00 | -$193.88M |
| 2024-12-31 | $83.33M | $83.33M | $33.57M | $208.52M | $0.00 | -$227.10M |
| 2023-12-31 | $90.24M | (m) | $37.21M | $232.27M | -$152.00K | -$263.49M |
| 2022-12-31 | $112.72M | (m) | $54.55M | $242.45M | -$84.00K | -$280.32M |
| 2021-12-31 | $470.35M | (m) | $51.83M | $181.44M | $13.41M | $127.84M |
| 2020-12-31 | $154.57M | $145.13M | $35.71M | $166.29M | $5.24M | -$111.25M |
| 2019-12-31 | $35.23M | $24.33M | $8.24M | $124.19M | -$2.75M | -$94.73M |
| 2018-12-31 | $218.50M | $176.07M | $9.64M | $83.87M | $4.18M | $99.94M |
| 2017-12-31 | $10.39M | $1.05M | $1.71M | $57.22M | $0.00 | -$73.17M |
| 2016-12-31 | $4.59M | (m) | (m) | $45.48M | -$435.00K | -$62.97M |
| 2015-12-31 | $7.59M | (m) | (m) | $17.28M | $0.00 | -$22.81M |
| 2014-12-31 | $6.12M | (m) | (m) | $4.96M | $0.00 | -$4.00M |
| 2013-12-31 | $6.09M | (m) | (m) | $5.05M | $0.00 | -$5.39M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |